트라베르 테라퓨틱스(TVTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $62.14 (+1.16%), 시가총액 $3.96B, 52주 범위 $14.09 ~ $44.91.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which ha
트라베르 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
트라베르 테라퓨틱스의 현재 주가는 $62.14 (+1.16%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
트라베르 테라퓨틱스의 시가총액은 약 $3.96B입니다.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's produ